跳至主要内容
临床试验/EUCTR2013-003573-10-GB
EUCTR2013-003573-10-GB进行中(未招募)1 期

Can Vitamin D supplementation improve Hepatitis C cure rates: A pilot multicentre randomised controlled clinical trial - The ViaDUCT study

niversity of Dundee & NHS Tayside0 个研究点目标入组 160 人开始时间: 2013年9月30日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Have confirmed hepatitis C with positive PCR for genotype 1 or 3
  • Are planned to commence on standard eradication therapy for HCV
  • Aged 18 or over
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 90
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 10

排除标准

  • Hepatitis C genotype other than 1 or 3
  • Previous treatment with interferon/ribivarin
  • Contraindications to interferon / ribavirin therapy
  • eGFR <30 ml/min (by MDRD4 method)
  • Currently decompensated liver disease
  • oAscites, encephalopathy or variceal bleeding
  • History of renal calculi
  • Serum calcium <2.15 mmol/L or >2.60 mmol/L
  • History of sarcoidosis, metastatic malignancy
  • Hepatocellular carcinoma (current or previous)
  • Taking >400 units/day of vitamin D
  • HIV positive
  • Breastfeeding
  • Of childbearing potential and not taking reliable contraception
  • Participation in another drug trial concurrently or within 30 days of screening for this one
  • Unable to provide written informed consent

研究者

发起方
niversity of Dundee & NHS Tayside

相似试验